Figure 3.
In vivo Vγ9Vδ2 T cell expansion following antigen and rhIL-2 treatment
(A) 7 pigtail macaques were treated with 1 of 4 different antigen treatment regimens along with rhIL-2 (0.8 x106 IU subcutaneously q24 h for 5 days) to stimulate in vivo Vγ9Vδ2 T cell expansion (1–2 animals per antigen treatment group). Peripheral blood mononuclear cells (PBMC), bronchoalveolar lavage fluid (BAL), rectal mucosal biopsies (Rectal Bx), and inguinal lymph node biopsies (LN Bx) were collected at the indicated timepoints pre- and post-antigen administration. Diagram created with BioRenderer.com.
(B) CD3+ Vγ9Vδ2 was identified from fresh PBMC and tissue samples using the indicated gating strategy.
(C) Representative FACS plots (Group 1) and frequencies of peripheral blood Vγ9Vδ2 T cells pre- and post-antigen and rhIL-2 treatment.
(D) Representative FACS plots (Group 1) and frequencies of Vγ9Vδ2 T cells in the BAL pre- and post-antigen and rhIL-2 administration.
(E) Vγ9Vδ2 T cell frequencies in rectal mucosa and inguinal lymph node biopsy samples pre- and post-antigen and rhIL-2 treatment.
Each point on the graphs represents an individual animal from each timepoint. Dotted red lines indicated the start of antigen and rhIL-2 treatment. Data collected from 1 experiment. IV; Intravenous, IT: Intratracheal.